Sarepta (SRPT) calls active after FDA approves eteplirsen

September 19, 2016 10:03 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Sarepta Therapeutics (NASDAQ: SRPT) September and October 43 calls are active after a post to the website of the FDA indicated that the regulator granted approval for eteplirsen, the company's treatment of Duchenne muscular dystrophy.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Add Your Comment